Clinical Trials Logo

Neuroendocrine Tumors clinical trials

View clinical trials related to Neuroendocrine Tumors.

Filter by:

NCT ID: NCT03220217 Not yet recruiting - Clinical trials for Gastro-Enteropancreatic Neuroendocrine Tumor

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Start date: July 30, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research is to define the optimal dose of 68Ga-OPS202 as a PET imaging agent to be used to detect and localize gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). 68Ga-OPS202 is a radiolabelled imaging agent to be used in association with Positron-Emission-Tomography (PET). 68Ga-OPS202 is made of two main components: 1) OPS202, an antagonistic somatostatin analogue which binds to the somatostatin receptor (type 2) present on the surface of the tumor cells and 2) Gallium 68, a radioisotope that combined with OPS202 can be seen in the PET scanner.

NCT ID: NCT03220087 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain

RECOSY
Start date: July 20, 2017
Phase: N/A
Study type: Observational

The objective of this study is to describe the use of resources and the costs associated with controlled or uncontrolled CS in patients with NETs in Spain.

NCT ID: NCT03217097 Not yet recruiting - Clinical trials for Neuroendocrine Carcinomas

O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents and Interest of Oxaliplatin in Patients With Unmethylated MGMT NET.

MGMT-NET
Start date: January 2018
Phase: Phase 2
Study type: Interventional

Neuroendocrine tumors (NET) are rare but their incidence is growing. Alkylating agents (ALKY) are one of the main systemic treatments used, at least for advanced pancreatic NETs, with a response rate of 30 to 40% and a median progression-free survival of 4 to 18 months. Chemotherapy is one of the few therapeutic weapons, along with everolimus, somatostatin analogs, and metabolic radiotherapy, for pulmonary NETs, called typical and atypical carcinoids, even if the level of proof of efficacy for these treatments is lower than for pancreatic NETs. Considering the available retrospective data, O6-Methylguanine-DNA methyltransferase (MGMT) appears to be a predictive factor of the response to ALKY. Oxaliplatin (OX) has demonstrated an interesting activity, with response rates between 17% and 30%. In a first retrospective study we showed that Gemox is effective in NET, and more recently that its activity is similar to that of ALKYs, but without being influenced by the MGMT status. Prospective studies are needed but our data suggests that ALKY should be offered first to patients with methylated MGMT tumors while Oxaliplatin-based chemotherapy should be offered first to patients with unmethylated MGMT tumors. In this project, we wish to evaluate the contribution of the MGMT methylation, evaluated in the tumor, in predicting the Objective Response (OR) in patients treated with ALKY and to carry out the first randomized phase II study comparing a treatment with alkylating agents to Oxaliplatin in patients with a pancreatic or broncho-pulmonary NET. The main objective of this study is to evaluate the usefulness of tumor MGMT methylation in the prediction of the Objective Response (OR) at 3 months in patients treated with ALKY for a NET, assessed using the RECIST v1.1 criteria by centralized reading carried out by an expert radiologist blinded to the results of the MGMT methylation.

NCT ID: NCT03211988 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

Entinostat Neuroendocrine (NE) Tumor

Start date: August 1, 2017
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm, multi-center Phase II trial of entinostat given as a 5 mg oral dose every week (days 1, 8, 15, and 22 of a 4-week cycle) in patients with relapsed or refractory abdominal neuroendocrine (NE) tumors. Patients will continue on treatment until disease progression or intolerable toxicity occurs.

NCT ID: NCT03204032 Recruiting - Clinical trials for Extrapancreatic Neuroendocrine Tumor

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

Start date: October 2016
Phase: Phase 2
Study type: Interventional

A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced Extrapancreatic Neuroendocrine Tumor

NCT ID: NCT03204019 Recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor

Start date: October 2016
Phase: Phase 2
Study type: Interventional

A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced Pancreatic Neuroendocrine Tumor

NCT ID: NCT03197012 Recruiting - Clinical trials for Neuroendocrine Tumor

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

Start date: July 1, 2017
Phase: Early Phase 1
Study type: Interventional

This is a prospective, pilot, single center, open-label study in patients with metastatic neuroendocrine tumor. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive a one-time administration of 90Y-DOTA-TOC via the hepatic artery. Participants in the correlative sub-study will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose, and undergo additional imaging and assessment.

NCT ID: NCT03190213 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma

Pembro NEC
Start date: September 2017
Phase: Phase 2
Study type: Interventional

This is an open label, non-randomized phase 2 study to assess overall response rate (ORR), clinical benefit rate (CBR), overall survival (OS) and progression free survival (PFS) in patients with poorly differentiated, high grade neuroendocrine tumors treated with pembrolizumab 200mg Q 3 Weeks.

NCT ID: NCT03183271 Completed - Clinical trials for Neuroendocrine Tumors

Proton Boost for Locally Advanced HEAD AND NECK TUMORS

Start date: July 16, 2012
Phase: N/A
Study type: Interventional

The aim of this research project is to test the local response and the acute toxicity (which can be observed within 90 days).

NCT ID: NCT03167853 Recruiting - Clinical trials for Neuroendocrine Tumors

Study of JS001 in Patients With Advanced Neuroendocrine Tumors

Start date: April 6, 2017
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, phase Ib study evaluating safety and efficacy of the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with neuroendocrine tumors who have failed in previous systemic treatment. 40 patients are enrolled and injected with the humanized anti-PD-1 antibody 3mg/mg every 2 weeks until disease progresses or unacceptable toxicity.